Weight loss drugs like Ozempic (Wegovy) have gained popularity among adults due to their effectiveness in shedding weight and treating other conditions. However, with about one in five US children having obesity, there’s growing concern over the safety of these medications in kids.
While research suggests that GLP-1 receptor agonists can be effective for children as young as 12, prescribing them to growing children raises concerns. Doctors argue that more time is needed to fully understand their long-term impact on development.
Pediatrician Dr. Chris Straughn believes that early obesity intervention and using medications like Ozempic (Wegovy) as a tool can be beneficial. However, Dr. Dan Cooper, a researcher at the University of California, Irvine’s School of Medicine, cautions that there are unknowns surrounding long-term effects.
Cooper emphasizes the importance of carefully weighing the benefits against potential risks and monitoring for any adverse reactions, such as depressive symptoms. He also stresses that parents should not blame themselves or their children for obesity and encourage healthy eating habits instead.
The FDA has approved Wegovy for use in kids aged 12, but there is ongoing research on younger children. Saxenda, a predecessor to Wegovy, showed promise in treating obese children between 6 and 12 years old. While early intervention can be beneficial, Cooper’s main concern is the lack of long-term data.
Ultimately, parents should consult their child’s doctor about potential GLP-1 use and be aware of the risks and benefits.
Source: https://medicalxpress.com/news/2024-12-weight-loss-drugs-ozempic-wegovy.html